Over 35 million people worldwide are living with Alzheimer's disease (AD) or a related disorder, and this number is expected to exceed 115 million by 2050.
In 2010, the worldwide costs of AD and related disorders (ADRD) were estimated at $604 billion, or 1% of GDP, and these costs are expected to reach $950 billion by 2025. These disorders thus represent a public health and fiscal crisis that is straining governments across the world.
The U.S. National Alzheimer's Plan aims to achieve effective prevention and treatment of Alzheimer's disease by 2025.
On November 6–7, 2013, the New York Academy of Sciences convened stakeholders from industry, academia, and government, as well as from nonprofit, advocacy, financial, and philanthropic organizations, to develop a research agenda focused on the 2025 goal of the U.S. National Plan.
The Alzheimer's Disease Summit: The Path to 2025 conference explored how to accelerate the development of new diagnostics and therapeutics, coordinating with government efforts to build research resources, reengineer drug-development systems, and identify innovative technologies and financing mechanisms.
The conference was jointly presented by the Academy's Alzheimer's Disease and Dementia Initiative, the Global CEO Initiative on Alzheimer's Disease, and the National Institute on Aging, National Institutes of Health.